ARMATA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $1.01M.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $1.03M.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $0.00.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $0.00.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $953.00K, a 3870.83% increase from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $24.00K, a 2399900.00% increase from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.00, a 100.00% decline from fiscal 2022.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $44.00K, a 63.64% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.04M 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $1.03M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $953.00K 10-K · filed 2026-03-25 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $0.00 derived: sum of 2 quarters · filed 2025-03-21 | $9.00K derived: sum of 3 quarters · filed 2025-03-21 | $24.00K 10-K · filed 2025-03-21 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $9.00K derived: sum of 2 quarters · filed 2024-11-13 | $24.00K 10-Q · filed 2024-11-13 | $23.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $24.00K 10-Q · filed 2024-08-13 | $23.00K derived: sum of 3 quarters · filed 2024-08-13 | |
| 2024-03-31 | $15.00K 10-Q · filed 2024-05-07 | $14.00K derived: sum of 2 quarters · filed 2024-05-07 | ||
| 2023-12-31 | -$999.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.00 10-K · filed 2024-03-21 | ||
| 2023-09-30 | $1.00K 10-Q · filed 2023-11-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $17.00K derived: sum of 2 quarters · filed 2023-03-16 | $44.00K 10-K · filed 2023-03-16 | |
| 2022-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $44.00K 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $27.00K 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $39.00K derived: sum of 2 quarters · filed 2022-03-17 | $39.00K derived: sum of 3 quarters · filed 2022-03-17 | $121.00K 10-K · filed 2022-03-17 |
| 2021-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $16.00K derived: sum of 2 quarters · filed 2021-11-10 | $98.00K 10-Q · filed 2021-11-10 | $98.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $82.00K 10-Q · filed 2021-08-12 | $82.00K derived: sum of 3 quarters · filed 2021-08-12 | |
| 2021-03-31 | $82.00K 10-Q · filed 2021-05-13 | $82.00K derived: sum of 2 quarters · filed 2021-05-13 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $14.00K 10-K · filed 2021-03-18 | ||
| 2020-09-30 | $14.00K 10-Q · filed 2020-11-12 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $533.74K derived: sum of 2 quarters · filed 2016-03-30 | $383.99K 10-K · filed 2016-03-30 | |
| 2015-09-30 | $533.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | $383.99K 10-Q · filed 2015-11-16 | ||
| 2015-06-30 | -$149.75K 10-Q · filed 2015-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |